Your Prescription for Success

Specialists Consulting for FDA & EMA Orphan Drug Development and Designations for Rare Diseases

A US-based corporation that operates as a not-for-profit, BioPharma Global offers FDA & EMA regulatory affairs and a complete suite of professional services to address the needs of emerging and growing biotech companies globally dedicated to rare disease research.

Regulatory Affairs Consulting and Human Capital Solutions


Clinical Network Services (CNS), an international clinical and regulatory service group, and BioPharma Global announced they have signed a cooperative partnership agreement. Read more here.


Regulatory Affairs

Human Capital Solutions

BioPharma Global News and Notes

Matinas BioPharma Achieves Statistical Endpoint for Success in Phase 2a Clinical Study of Orally-Administered MAT2203 for the Treatment of Chronic Refractory Mucocutaneous Candidiasis

Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company focused on developing innovative anti-infectives for orphan indications, today announced that investigators from the National Institutes of Health (“NIH”) have relayed to the Company positive... READ MORE